Avience Biomedicals IPO GMP, Review, Date, Price, Subscription & Allotment Status 2026

Avience Biomedicals Limited is launching its SME IPO on the NSE SME platform with a price band of Rs 196 to Rs 208 per share. The issue opens on June 18, 2026, and closes on June 22, 2026. The total issue size is Rs 30.24 crore, entirely a fresh issue with no offer for sale component.

The grey market premium (GMP) for Avience Biomedicals IPO today stands at Rs 40, pointing to an estimated listing price of Rs 248 and a potential listing gain of around 19.23% over the upper price band.

The company is a Noida-based diagnostics and IVD (In-Vitro Diagnostic) products company incorporated in June 2024. It plans to use IPO proceeds primarily to build a new manufacturing unit inside the YEIDA Medical Device Park in Gautam Buddha Nagar, Uttar Pradesh.

📋 Table of Contents

Avience Biomedicals IPO Key Details

Avience Biomedicals IPO GMP Today

The Avience Biomedicals IPO GMP today is Rs 40, as of June 15, 2026. Based on this GMP, the estimated listing price works out to Rs 248, which is approximately 19.23% above the upper price band of Rs 208.

A rising GMP may indicate positive early sentiment, but it should not be viewed as a guarantee of listing gains. GMP is an unregulated, informal market indicator and can shift quickly based on subscription trends and broader market conditions.

Avience Biomedicals IPO GMP Trend

The GMP moved from zero to Rs 40 on June 15, suggesting early interest is building ahead of the subscription window. For a retail applicant receiving one lot of 1,200 shares, the estimated listing gain at current GMP works out to approximately Rs 48,000.

For live GMP updates across all active SME IPOs, track the IPOwiz Live GMP Tracker.

Avience Biomedicals IPO Date and Timeline

Avience Biomedicals IPO Lot Size and Minimum Investment

SME IPOs require a higher minimum investment compared to mainboard issues. Here is the full lot size and investment breakdown for Avience Biomedicals IPO.

The minimum retail investment of Rs 2,49,600 is a meaningful capital commitment. Investors should assess their portfolio liquidity carefully before applying, particularly given the company's short operating history.

Avience Biomedicals IPO Subscription Status

Subscription data will be updated here once bidding opens on June 18, 2026.

For real-time subscription updates during the bidding window, follow the IPOwiz Telegram channel.

Avience Biomedicals IPO Reservation Structure

About Avience Biomedicals Limited

Avience Biomedicals Limited was incorporated in June 2024 and is based in Noida, Uttar Pradesh. The company designs, develops, and distributes In-Vitro Diagnostic (IVD) products, molecular diagnostic kits, and genomic tools. It operates in the B2B and B2G segments, supplying to pathology labs, public hospitals, microbiology centers, and academic research institutions.

Product Portfolio

• Rapid Test Kits: Sold under the AVISURE brand, including the AVISURE Dengue Combo Test, Malaria Rapid Test (Pf/Pv), and AVISURE Syphilis Rapid Test
• Biochemistry Analyzers and Reagents: Includes the BS-240 Fully Auto Analyzer and AVIENBIO reagent lines
• Molecular Diagnostics: PCR-based kits including the COVID-19 Hid RTqPCR Assay
• Hematology Devices: BC-20s 3-Part Hematology Analyzer
• Medical Support Devices: Oxy-5 and Oxy-10 oxygen concentrators, Viral Transport Media (VTM) tubes

Beyond its own branded products, Avience also acts as a regional distributor for global medical equipment manufacturers, which helps it maintain consistent revenue from institutional procurement channels.

Manufacturing Facility and YEIDA Expansion

The company currently operates from a leased facility in Noida, which provides direct access to Delhi-NCR's medical distribution networks.

The primary use of IPO proceeds is to build a new manufacturing unit at Industrial Plot No. 70, Sector 28, inside the YEIDA Medical Device Park in Gautam Buddha Nagar, Uttar Pradesh. This government-supported park offers infrastructure advantages including stable utility supply, shared processing centers, and state-level tax benefits for medical device manufacturers.

The new facility is expected to significantly increase production capacity once operational. However, investors should note that capital expenditure projects of this nature typically involve a gestation period of 12 to 18 months before the new plant reaches optimal utilization. This could temporarily weigh on net profit margins during the ramp-up phase.

Avience Biomedicals IPO Financial Performance

The company has shown strong revenue growth in a short period. Below are the audited consolidated financials.

Revenue nearly doubled from FY24 to FY25, and the 10-month FY26 figure of Rs 41.94 crore suggests an annualized run rate of approximately Rs 50 crore.

One point worth noting: the standalone revenue for the same 10-month FY26 period was Rs 28.85 crore, which is notably lower than the consolidated figure. This gap suggests that a meaningful portion of consolidated revenue comes from subsidiary operations or inter-company trading. Investors should review this carefully in the RHP.

Key Financial Ratios

• PAT Margin: 15.72% (FY25) | 13.69% (10M FY26)
• EBITDA Margin: 24.82% (FY25) | 24.70% (10M FY26)
• ROE / RoNW: 50.14% / 49.89% (FY25) | 22.38% (10M FY26 annualized)
• ROCE: 24.84% (FY25) | 16.99% (10M FY26)
• Debt-to-Equity: 0.94x
• Price to Book Value: 2.94x

The ROE compression from 50% in FY25 to around 22% in FY26 is a natural pattern as the equity base expands ahead of a public listing. The EBITDA margin holding above 24% is a positive sign of pricing discipline within the diagnostics segment.

Avience Biomedicals IPO Debt Position

The company carries a meaningful debt load that investors should factor into their assessment.

The debt-to-equity ratio stands at 0.94x as of January 2026. Importantly, the IPO proceeds do not include any allocation for debt repayment. This means the existing borrowings will remain on the balance sheet post-listing, and the company will need to sustain strong revenue growth to comfortably service its interest obligations alongside the new capital expenditure at YEIDA.

Avience Biomedicals IPO Valuation

At the upper price band of Rs 208, the post-issue P/E works out to 16.56x based on diluted earnings. This appears reasonable when compared to larger mainboard diagnostics and biotech companies, which typically trade at 30x or higher. However, the comparison is not straightforward given the significant difference in scale, track record, and liquidity.

The 16.56x multiple leaves limited room for earnings disappointment, particularly if the YEIDA facility faces construction delays or if revenue growth moderates.

Objects of the Avience Biomedicals IPO

The fresh issue proceeds of Rs 28.53 crore will be deployed as follows:

The allocation toward real asset creation is a positive signal. The absence of any OFS component means no promoter or early investor is using this IPO as an exit route.

Avience Biomedicals IPO Risks

• Short Operating History: The company was incorporated in June 2024. With less than two full financial years of operations, there is limited data to assess how management performs through market cycles, competitive pressure, or demand slowdowns.
• YEIDA Facility Gestation Period: The new manufacturing plant will require 12 to 18 months to become fully operational. During this period, the company will carry higher depreciation and fixed costs without a proportionate increase in production output, which could compress net margins temporarily.
• Debt Remains Post-IPO: With Rs 26.73 crore in borrowings and no debt repayment planned from IPO proceeds, interest servicing will continue to be a recurring cost pressure.
• Competitive Sector: The IVD and rapid test kit market includes large mainboard players, established institutional distributors, and low-cost imports. Sustaining market share requires continuous product development and cost control.
• Standalone vs. Consolidated Revenue Gap: The difference between standalone and consolidated revenue figures warrants closer scrutiny of subsidiary contributions and related-party transactions.

Avience Biomedicals IPO Review: Should You Apply?

Avience Biomedicals presents a credible early-stage growth story in the diagnostics space. The financials show strong revenue momentum, healthy EBITDA margins above 24%, and a 100% fresh issue structure with clear capital deployment plans. The post-issue P/E of 16.56x is not stretched for the diagnostics sector, and the YEIDA facility investment signals a genuine intent to scale manufacturing capacity.

That said, the company is only two years old. The debt load is rising, the new facility will take time to generate returns, and the standalone-to-consolidated revenue gap needs a closer look.

For listing gain seekers: The current GMP of Rs 40 suggests moderate positive sentiment. Whether it holds through subscription will depend on Day 2 and Day 3 QIB participation. Monitor subscription velocity before the final day.

For long-term investors: The diagnostics sector has strong structural demand, but this company needs at least two to three more years of consistent performance before it can be evaluated with confidence. Conservative investors may prefer to wait for post-listing price discovery before taking a position.

Avience Biomedicals IPO Allotment Status & Chances

The basis of allotment for Avience Biomedicals IPO is expected to be finalized on June 23, 2026. Refunds will be initiated and shares will be credited to demat accounts on June 24, 2026.

Given the compact issue size of 14.53 lakh shares, oversubscription is possible. If the issue is heavily oversubscribed in the retail category, allotment will be determined by a computerized lottery system. Allotment probability analysis will be updated here once Day 3 subscription data is available on June 22, 2026.

Key factors that will influence allotment chances:

• Total retail applications received
• Retail category oversubscription multiple
• Whether QIB and NII categories are fully subscribed

In SME IPOs with a small retail quota (4,81,200 shares in this case), even moderate oversubscription can significantly reduce individual allotment probability.

Frequently Asked Questions